Kamada Ltd. (NASDAQ:KMDA - Get Free Report) crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $5.96 and traded as high as $6.72. Kamada shares last traded at $6.64, with a volume of 45,913 shares trading hands.
Wall Street Analyst Weigh In
Separately, HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, November 14th.
Get Our Latest Report on Kamada
Kamada Stock Performance
The stock has a market cap of $390.86 million, a price-to-earnings ratio of 24.29 and a beta of 0.98. The stock's 50-day simple moving average is $5.96 and its two-hundred day simple moving average is $5.63.
Institutional Trading of Kamada
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio acquired a new stake in shares of Kamada in the third quarter worth $77,000. Plato Investment Management Ltd acquired a new stake in Kamada in the 3rd quarter worth $117,000. Finally, Y.D. More Investments Ltd increased its holdings in shares of Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company's stock worth $3,643,000 after purchasing an additional 690,842 shares during the period. Institutional investors and hedge funds own 20.38% of the company's stock.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
Read More
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
